ABVD regimen
WikiDoc Resources for ABVD regimen |
Articles |
---|
Most recent articles on ABVD regimen Most cited articles on ABVD regimen |
Media |
Powerpoint slides on ABVD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ABVD regimen at Clinical Trials.gov Clinical Trials on ABVD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ABVD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ABVD regimen Discussion groups on ABVD regimen Patient Handouts on ABVD regimen Directions to Hospitals Treating ABVD regimen Risk calculators and risk factors for ABVD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for ABVD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen
Overview
ABVD regimen refers to an immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.[1][2]
Regimen
H – Doxorubicin (Hydroxydaunomycin)
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Coiffier, Bertrand (2002-01-24). "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma". The New England Journal of Medicine. 346 (4): 235–242. doi:10.1056/NEJMoa011795. ISSN 1533-4406. PMID 11807147. Unknown parameter
|coauthors=
ignored (help) - ↑ Kluin-Nelemans, H. C. (2012-08-09). "Treatment of older patients with mantle-cell lymphoma". The New England Journal of Medicine. 367 (6): 520–531. doi:10.1056/NEJMoa1200920. ISSN 1533-4406. PMID 22873532. Unknown parameter
|coauthors=
ignored (help)